The important announcements for Hong Kong stocks yesterday are as follows:

1) Company news

$BAY AREA DEV (00737.HK)$: In April, the total monthly toll revenue for the Guangzhou-Shenzhen Expressway, Guangzhou-Zhuxi Expressway and the Yanjiang Expressway (Shenzhen section) was approximately 238 million yuan, 104.5 million yuan, and 52.284 million yuan respectively, up 4%, 6% and -2% year-on-year respectively, for a total of about 395 million yuan.

$CHANGJIU HLDGS (06959.HK)$: The number of car dealerships that the company provides car dealership operation and management services has reached 104, breaking the milestone of 100.

$CHINA VANKE (02202.HK)$: Successfully transferred the Shenzhen Bay Super Headquarters plot of over 2.2 billion yuan.

$ZHEJIANGEXPRESS (00576.HK)$: The subsidiary Zheshang Securities transferred 7.6933% of Guodu Securities held by Guohua Energy for about 1,09.4 billion yuan.

$ICBC (01398.HK)$: It is planned to invest 21.5 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund.

$ABC (01288.HK)$: It is planned to invest 21.5 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund.

$BANK OF CHINA (03988.HK)$: It is planned to invest 21.5 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund.

$CCB (00939.HK)$: It is planned to invest 21.5 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund.

$BANKCOMM (03328.HK)$: It is planned to invest 20 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund

$PSBC (01658.HK)$: It is planned to invest 8 billion yuan in the third phase of the National Integrated Circuit Industry Investment Fund.

$CHINA BLUECHEM (03983.HK)$: Subscribe to 500 million yuan structured deposit products.

$SANXUN GROUP (06611.HK)$: In the first 3 months, cumulative contract sales amounted to 158 million yuan, a year-on-year decrease of 62.65%.

$FOSUN PHARMA (02196.HK)$: Desloratadine oral solution approved for drug registration. According to the data, sales of similar products in China in 2023 were approximately RMB 315 million; the drug registration application for norepinephrine bitartrate independently developed by Jinzhou Aohong Pharmaceutical was accepted, and the sales volume of similar products in China in 2023 was approximately RMB 1,967 million.

$POKFULAM (00225.HK)$: Announced interim results for the year ended March 31, with revenue of HK$83.355 million, up 6.77% year on year; loss of approximately HK$218 million, changing from profit to loss year over year.

$NAMESON HLDGS (01982.HK)$: Annual profit is expected to increase to approximately HK$355-395 million.

$HUAFA PPT SER (00982.HK)$: Received a premium of about 30.63% from Huajin Investment and was privatized.

$COSMOS MACH (00118.HK)$: Completed the sale of all shares of Hong Kong Bunge and all shares of Shenzhen Bunge.

2) Repurchase news

$TENCENT (00700.HK)$: Approximately HK$1.04 billion was spent to repurchase 2.69 million shares at a repurchase price of HK$363.20-377.40.

$HSBC HOLDINGS (00005.HK)$: A repurchase of 3.5 million shares was spent at HK$240 million, at a repurchase price of HK$68.3-69.

$HANG SENG BANK (00011.HK)$: Approximately HK$338.454 million was spent to repurchase 300,000 shares at a repurchase price of HK$110.500-HK$113.700.

$AIA (01299.HK)$: Spend HK$15.627,800 to repurchase 255,000 shares at a repurchase price of HK$60.2-62.15.

$KUAISHOU-W (01024.HK)$: A repurchase of 175,400 shares was spent at HK$9.718 million, at a repurchase price of HK$55.8-57.

edit/new